UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phosphorylation of Synucleins by Members of the Polo-like Kinase Family

The Journal of biological chemistry, 2010-01, Vol.285 (4), p.2807-2822

2010

Volltextzugriff (PDF)

Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils

Neurobiology of disease, 2015-02, Vol.74, p.89-101

2015

Volltextzugriff (PDF)

Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology

Neurobiology of disease, 2015-07, Vol.79, p.81-99

2015

Volltextzugriff (PDF)

Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region

PloS one, 2008-10, Vol.3 (10), p.e3394-e3394

2008

Volltextzugriff (PDF)

Hydrogen Peroxide Is Generated during the Very Early Stages of Aggregation of the Amyloid Peptides Implicated in Alzheimer Disease and Familial British Dementia

The Journal of biological chemistry, 2005-10, Vol.280 (43), p.35789-35792

2005

Volltextzugriff (PDF)

Assessment of the Anti-Amyloidogenic Properties of Essential Oils and Their Constituents in Cells Using a Whole-Cell Recombinant Biosensor

Brain sciences, 2024-01, Vol.14 (1), p.35

2024

Volltextzugriff (PDF)

Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts

BMC complementary medicine and therapies, 2020-03, Vol.20 (1), p.73-21, Article 73

2020

Volltextzugriff (PDF)

Entacapone and Tolcapone, Two Catechol O-Methyltransferase Inhibitors, Block Fibril Formation of α-Synuclein and β-Amyloid and Protect against Amyloid-induced Toxicity

The Journal of biological chemistry, 2010-05, Vol.285 (20), p.14941-14954

2010

Volltextzugriff (PDF)

Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions

The Journal of neuroscience, 2010-03, Vol.30 (9), p.3184-3198

2010

Volltextzugriff (PDF)

Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease

The Journal of neuroscience, 2012-02, Vol.32 (5), p.1536-1544

2012

Volltextzugriff (PDF)

Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease

The FASEB journal, 2006-03, Vol.20 (3), p.419-425

2006

Volltextzugriff (PDF)

Detection of elevated levels of soluble -synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies

Brain (London, England : 1878), 2009-04, Vol.132 (4), p.1093-1101

2009

Volltextzugriff (PDF)

Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of α-Synuclein

The Journal of biological chemistry, 2008-06, Vol.283 (24), p.16895-16905

2008

Volltextzugriff (PDF)

Detection of elevated levels of soluble α-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies

Brain (London, England : 1878), 2009-04, Vol.132 (4), p.1093-1101

2009

Volltextzugriff (PDF)

Designing Peptide Inhibitors for Oligomerization and Toxicity of Alzheimer's β-Amyloid Peptide

Biochemistry (Easton), 2008-02, Vol.47 (7), p.1984-1992

2008

Volltextzugriff (PDF)

Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity

Frontiers in aging neuroscience, 2014-08, Vol.6, p.197

2014

Volltextzugriff (PDF)

α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma

The FASEB journal, 2003-10, Vol.17 (13), p.1-16

2003

Volltextzugriff (PDF)

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers

Frontiers in aging neuroscience, 2014-09, Vol.6, p.248-248

2014

Volltextzugriff (PDF)

A strategy for designing inhibitors of α ‐synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders

The FASEB journal, 2004-08, Vol.18 (11), p.1315-1317

2004

Volltextzugriff (PDF)

α-Synuclein aggregation and modulating factors

Sub-cellular biochemistry, 2012, Vol.65, p.109

2012

Volltextzugriff (PDF)

Elevated levels of cerebrospinal fluid Î±-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers

Frontiers in aging neuroscience, 2014-09, Vol.6

2014

Volltextzugriff (PDF)

Structure activity relationship of phenolic acid inhibitors of Î±-synuclein fibril formation and toxicity

Frontiers in aging neuroscience, 2014-08, Vol.6

2014

Volltextzugriff (PDF)

Fe(II)‐induced DNA damage in α‐synuclein‐transfected human dopaminergic BE(2)‐M17 neuroblastoma cells: detection by the Comet assay

Journal of neurochemistry, 2003-11, Vol.87 (3), p.620-630

2003

Volltextzugriff (PDF)

Alpha-synuclein and the pathogenesis of Parkinson's disease

Protein and peptide letters, 2004-06, Vol.11 (3), p.229-237

2004

Volltextzugriff (PDF)

Entacapone and Tolcapone, Two Catechol O-Methyltransferase Inhibitors, Block Fibril Formation of a-Synuclein and b-Amyloid and Protect against Amyloid-induced Toxicity

The Journal of biological chemistry, 2010-05, Vol.285 (20), p.14941-14954

2010

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phosphorylation of Synucleins by Members of the Polo-like Kinase Family

Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils

Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology

Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region

Hydrogen Peroxide Is Generated during the Very Early Stages of Aggregation of the Amyloid Peptides Implicated in Alzheimer Disease and Familial British Dementia

Assessment of the Anti-Amyloidogenic Properties of Essential Oils and Their Constituents in Cells Using a Whole-Cell Recombinant Biosensor

Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts

Entacapone and Tolcapone, Two Catechol O-Methyltransferase Inhibitors, Block Fibril Formation of α-Synuclein and β-Amyloid and Protect against Amyloid-induced Toxicity

Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions

Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease

Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease

Detection of elevated levels of soluble -synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies

Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of α-Synuclein

Detection of elevated levels of soluble α-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies

Designing Peptide Inhibitors for Oligomerization and Toxicity of Alzheimer's β-Amyloid Peptide

Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity

α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers

A strategy for designing inhibitors of α ‐synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders

α-Synuclein aggregation and modulating factors

Elevated levels of cerebrospinal fluid Î±-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers

Structure activity relationship of phenolic acid inhibitors of Î±-synuclein fibril formation and toxicity

Fe(II)‐induced DNA damage in α‐synuclein‐transfected human dopaminergic BE(2)‐M17 neuroblastoma cells: detection by the Comet assay

Alpha-synuclein and the pathogenesis of Parkinson's disease

Entacapone and Tolcapone, Two Catechol O-Methyltransferase Inhibitors, Block Fibril Formation of a-Synuclein and b-Amyloid and Protect against Amyloid-induced Toxicity

Suchergebnisse filtern